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Abstract
Background: Magnesium was reported to reduce both the anesthetic requirements and the period needed to
reach a bi-spectral index value of 60 when used intra-operatively (Br J Anaesth 83:302-20, 1999; Anesth Analg
20:1273-5, 1988; Br J Anaesth 89:594-8, 2002; Anesth Analg 87:206-10, 1998; Br J Anaesth 89:594-8, 2002; Br J
Anaesth 94:438-41, 2005) and to minimize the emergence agitation (Anaesthesia 61:1058-63, 2006). Previous studies
examined the influence of magnesium on the anesthetic requirements while the bi-spectral Index values were kept
within a constant range. We evaluated the effect of intraoperative magnesium on the bi-spectral index values
during pediatric anesthesia while we kept other anesthetic variables unchanged.
Methods: Eighty pediatric patients with ASA physical status I, age 2–8 years and scheduled for minor infra-umbilical
elective procedures included in a prospective randomized controlled study. We randomly divided patients into two
groups. Group I (40 patients); received a bolus dose 50 mg/kg of magnesium sulphate followed by an infusion at
rate of 15 mg/kg/h throughout the procedure. Group II (40 patients); received the same amount in the form of
ringer acetate for blinding. We compared between the groups regarding: 1) BIS values. 2) Hemodynamic
parameters. 3) Arterial oxygen saturation 4) End-tidal CO2 5) Respiratory rate and 6) Tidal volume.
Results: Magnesium group (Group I) showed significantly lower BIS values and shorter time to achieve BIS values
below 60. Respiratory parameters (tidal volume and respiratory rate) were significantly lower in the magnesium
group. Otherwise, no significant differences between the study group and the control group were detected.
Discussion: Our study has the advantage of evaluating the direct effect of magnesium sulphate on the Bi-spectral
index scale with keeping other intraoperative factors almost constant (as the type of operations, induction and
maintenance techniques, end-tidal anesthetic concentration, analgesia and mode of ventilation) for accurate
assessment.
Conclusion: Magnesium produced significantly lower BIS values, less time to reach BIS values below 60, lower tidal
volume and lower respiratory rate during pediatric general anesthesia.
Trial registration: Pan African Clinical Trial Registry, www.pactr.org, PACTR201312000666231. Registered at 6
October 2013.
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Background
Magnesium is a natural cation that represents the fourth
most predominant cation in the body and the second
most abundant intracellular cation. It has many essential
biological functions as energy metabolism and nucleic
acid synthesis, trans-membrane ion exchange and regu-
lation of adenylate cyclase; muscle contractility; neuronal
function and neuro-transmitter release. Magnesium has
been known to be a physiological calcium antagonist [1].
Rats treated with magnesium showed a 60 % reduction in
minimum alveolar concentration of halothane [2] this result
was explained as a central effect of magnesium. Magnesium
administration during total intravenous anaesthesia pro-
duced a significant reduction in the requirements for anaes-
thetic drugs; propofol, remifentanil and vecuronium [3].
Various studies [4–9] revealed that the perioperative
magnesium can reduce the anaesthetic demands and the
time needed to reach a BIS value of 60. In addition, mag-
nesium has been reported to have anti-nociceptive effects
in animal and human models of pain, and to reduce intra-
operative analgesic consumption [4–9]. Moreover, magne-
sium could decrease post-operative agitation following
tonsillectomy using sevoflurane anesthesia [10].
Although Bi-spectral index may not be accepted by some
authors [11] as a monitor for depth of anesthesia superior
to other methods yet BIS is the most accepted monitor of
depth of sedation and anaesthesia in pediatric [12–17].
Previous studies [4–9] examined the effects of magne-
sium on the anesthetic doses needed to keep bi-spectral
Index values within a fixed range (40–60).
Our present randomized controlled study evaluated
the influence of intraoperative magnesium on BIS values
while keeping other anesthetic variables almost constant
during pediatric anesthesia.
Methods
We carried out a prospective, randomized controlled
study at Beni-Suef University Hospital in the period from
the May 2013, to September 2013, after approval by the
local research and ethics committee (Faculty of medicine-
Beni Suef University- Research Ethical Committee). The
trial was registered at Pan African Clinical Trial Registry
(trial number: PACTR201312000666231).
We obtained a written form of informed consent from
the parents in charge. We included 80 children (Fig. 1),
ASA physical status I, aged 2–8 years scheduled for minor
infra-umbilical surgeries in the supine position (e.g. her-
niorrhaphy, hypospadias, hydrocele etc.) in the study. Ex-
clusion criteria included patients with head anomalies (e.g.
microcephaly, hydrocephalus), Down syndrome, cerebral
palsy, brain tumors, epilepsy and patients scheduled for
major or head and neck surgery or surgeries in non-supine
position. Patients underwent routine preoperative evalu-
ation including history, examination and investigations.
According to the protocol in our hospital, patients
received premedication with intramuscular midazolam
0.05 mg/ kg and atropine 0.01 mg/kg thirty minutes
before induction of anesthesia by inhalation of sevoflur-
ane aiming for end-tidal sevoflurane concentration of
2 volume % through a face mask. An intravenous
cannula was inserted after loss of consciousness. For
randomization, a computer-generated random num-
bers was used and the numbers were concealed in
opaque sealed envelopes. Patients were randomly
assigned to either group I (Magnesium) or group II
(Control). Group I (n = 40) received magnesium
sulphate with a priming dose of 50 mg/kg over ten
minutes. Infusion started immediately after insertion
of an intravenous line followed by an infusion at rate
of 15 mg/kg/h throughout the procedure. Group II
(n = 40) received balanced solution (ringer acetate)
with the same volume and infusion rate as for group
I with the attended anesthetist was unaware which solu-
tion was used for blinding. After the application of stand-
ard monitoring, an inhalation of sevoflurane ensured an
adequate depth of anesthesia with end-tidal sevoflurane
concentration of 2 volume %.
The patient’s airway was secured by laryngeal mask
airway (LMA™) with the appropriate size used according
to the weight of the patient. The volume of cuff inflation
was according to the recommendations of the manufac-
turer. The LMA™ was connected to a standard pediatric
circle circuit connected to the anesthesia workstation
(Zeus® Drӓger anaesthesia workstation, Drӓger Medical,
Lübeck, Germany) with side stream capnogram. Manual
ventilation was performed to ensure proper position of
LMA™ by obtaining three square-shaped waves of capno-
graphy with adequate chest expansion. Manual assisted
ventilated until spontaneous respiration resumed was
done. The patients continued with unassisted spontaneous
ventilation.
For intraoperative analgesia, all patients received caudal
epidural block (bupivacaine 0.25 % at a volume of 1 ml/kg)
and paracetamol suppository at a dose of 15 mg/kg. End-
tidal sevoflurane concentration was maintained at 2 vol-
ume %. The inspired sevoflurane concentration was not
recorded as it was changing rapidly and controlled auto-
matically together with the fresh gas flow by the anesthesia
machine (Zeus® Drӓger anaesthesia workstation, Drӓger
Medical, Lübeck, Germany) in order to maintain expired
sevoflurane concentration of 2 volume %.
Respiratory parameters that included respiratory rate,
expired tidal volume, end-tidal CO2, and SpO2 were
monitored continuously and recorded every ten minutes
throughout the procedure. Tidal volume was measured
using a spirometer sensor at the patient’s end. Side
stream capnography was used to monitor end-tidal
carbon dioxide concentration. The electrodes of the bi-
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spectral index were applied on the patient’s forehead,
and BIS values were recorded immediately after induc-
tion of anesthesia then every ten minutes and till end of
the operation. Hemodynamic parameters that included
heart rate, systolic blood pressure and diastolic blood
pressure were monitored continuously and recorded
every ten minutes. The mean values of each of these
parameters were computed for each patient, and these
values were used for statistical analysis.
At the end of the surgery, we stopped the infusion of a
balanced solution or magnesium sulphate, discontinued
inhaled anesthetic, removed LMA while the patient was
at sevoflurane end tidal concentration of 2 volume %.
Then we allowed the patient to emerge from anesthesia
then transferred to PACU. We recorded any complica-
tions while conducting anesthesia, recovery or at PACU.
Statistical analysis
Assuming α error = 0.05 (two-tailed) and β error = 0.1.
Sample size of 34 patients, allocated into one group, will
have a power of 90 % to determine an assumed clinically
significant difference of 5 % (effect size d = 0.6) or more
between the paired measurements of BIS value in
magnesium and control groups. t- Test for matched
pairs was used to estimate the sample size. The sample
size was calculated using Power Analysis and Sample
Size 12 software (NCSS, Kaysville, UT, USA).
Fig. 1 CONSORT flowchart showing the number of patients at each phase of the study
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Data are expressed as mean ± SD. Analysis of variance
(ANOVA) test was used for comparison between means
of the two groups. For all comparisons, we considered
P < 0.05 statistically significant. We used software
version 21 of statistical package for social science
(SPSS version 21, Chicago, IL, USA).
Results
The study included 80 patients in two equal groups; Group
I (magnesium group), Group II (control group). We did
not detect statistically significant differences between the
groups regarding age, sex, weight and performed surgical
procedures (Table 1).
No significant difference between the groups was
reported regarding hemodynamic parameters (heart
rate, systolic blood pressure and diastolic blood pres-
sure) (Table 2).
BIS values were lower in the magnesium group than in
the control group, and this reduction was statistically
significant at 20 to 80 min of intraoperative time
(Table 3). All patients in the magnesium group reached
BIS values less than 60 in 20 min while patients in the
control group required 30 min to do so, this depended
on the highest BIS value within the group and not the
mean BIS value for the group.
Tidal volume was lower in the magnesium group than
in the control group, and this decrease was statisti-
cally significant throughout the operation (Table 4).
Respiratory rate was significantly lower in the magnesium
group till 60 min of the intra-operative time (Table 5).
We did not detect statistically significant difference
in End-tidal carbon dioxide concentration (Table 6)
or arterial oxygen saturation.
In conclusion, magnesium sulphate group had lower
BIS values, shorter time to achieve BIS values below 60,
lower tidal volume, and lower respiratory rate with no
significant differences in hemodynamic parameters or
end-tidal CO2 were reported. In either group, no
complications were reported.
Discussion
Our study revealed that magnesium sulphate significantly
reduced the time needed to achieve a BIS value below 60
for all patients (20 min. in the magnesium group versus
30 min. in the control group). Magnesium significantly re-
duced the BIS values, tidal volume and the respiratory rate.
The end-tidal CO2 was comparable between the groups.
No significant difference in hemodynamic parameters and
no complications were reported.







Age (years) 5.7 ± 2.1 6.4 ± 2.2 0.731
Sex (M/F) 17/23 21/19 0.124
Weight (kg) 20.3 ± 4.5 22.4 ± 5.6 0.694
Surgical procedures
Inguinal herniorrhaphy 17 25 0.08
Hypospadias 14 10 0.07
Hydrocele 6 4 0.09
Undescended testis 2 1 0.06
Cystoscopy 1 0 0.06
M male, F female, Kg kilogram
Data of age and weight are as mean ± standard deviation
P values ≤ 0.05 are considered statistically significant
Table 2 Hemodynamic parameters in both groups
HR SBP DBP
Group I Group II P value Group I Group II P value Group I Group II P value
After induction 112.9 ± 15.1 118.8 ± 16.3 0.630 102.4 ± 10.1 108.9 ± 11.9 0.281 61.6 ± 8.7 65.7 ± 6.6 0.374
10 min. 109.9 ± 13.3 113.6 ± 15.5 0.746 103.5 ± 10 107.6 ± 10.8 0.317 64.2 ± 10.3 64.8 ± 6.3 0.709
20 min. 106 ± 13.3 109 ± 14.8 0.821 102 ± 10.5 106.7 ± 11.4 0.477 65.5 ± 9.8 64.2 ± 6.5 0.532
30 min. 103 ± 12.4 104.3 ± 14.6 0.955 100.5 ± 10.5 105.7 ± 10.7 0.395 63.1 ± 10 64.4 ± 6 0.803
40 min. 99.2 ± 13 102.4 ± 13.1 0.852 96.7 ± 9.1 103.7 ± 11.5 0.271 61.4 ± 9 63.2 ± 7.4 0.857
50 min. 93.4 ± 11.9 99.3 ± 12.6 0.483 97.9 ± 9.9 99.6 ± 9.5 0.728 61.9 ± 9.5 61.6 ± 7.3 0.987
60 min. 89.1 ± 11.2 96.2 ± 11.7 0.411 102.7 ± 14.2 98.3 ± 7.9 0.677 61 ± 9.6 61.9 ± 7.6 0.596
70 min. 89.7 ± 10.5 91.5 ± 17.7 0.990 103.3 ± 12.1 102.5 ± 10.6 0.673 60 ± 16.5 68 ± 9.9 0.803
80 min. 87 ± 8.9 89.5 ± 17.7 0.978 102 ± 6.9 102 ± 14.1 0.732 59.3 ± 13.7 66.5 ± 12 0.786
Group I (Magnesium sulphate group)
Group II (Control group)
Data are as mean ± standard deviation
SBP systolic blood pressure
DBP diastolic blood pressure
HR heart rate
P values ≤ 0.05 are considered statistically significant
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Although there is no solid evidence for the use of
BIS as a method to prevent awareness in pediatric
anesthesia, there is no doubt that BIS is a useful moni-
tor for depth of anesthesia. We used BIS to evaluate the
central effect of magnesium as BIS has been used in
pediatric age group as an adequate monitor for level of
sedation and anesthesia [12–17]. Also BIS was considered
as a valuable method to prevent awareness in the practice
of anesthesia with an adequate level of general anesthesia
and a low risk of intra-operative awareness accompany BIS
values of 40 to 60 [18].
Our study has the advantage of evaluating the direct
effect of magnesium sulphate on the Bi-spectral index
scale with keeping other intraoperative factors almost
constant (as the type of operations, induction and
maintenance techniques, end-tidal anesthetic concen-
tration, analgesia and mode of ventilation) for accurate
assessment. While previous studies [4–9] that
examined the effect of using intra-operative magne-
sium depended on evaluating the change in the
demanded doses of intravenous anesthetics, inhaled
anesthetics, narcotics or muscle relaxants to keep BIS
values within a constant range, that BIS range was
from 40 to 60 which may be considered a relatively
wide range to be relied on to evaluate the effect of
magnesium on anesthetic requirements. In other
words, it is easier to control drug doses and measure
variation in BIS values to evaluate the direct effect of
magnesium rather than keeping BIS values within a
relatively wide range (40–60) and measuring drug
dosing. Also drug dosing is an indirect measure of
the central effect of magnesium while BIS values can
be considered as a direct monitor of that effect.
Our study is one of the few studies [10, 19–21] that
examined the effects of intraoperative magnesium
sulphate in pediatric anesthesia. These studies [10, 19–21]
Table 4 Tidal volume (ml) in both groups





After induction 131.4 ± 43.9 176.3 ± 44.5 0.003*
10 min. 131.0 ± 40.8 177.8 ± 42.5 0.001*
20 min. 131.5 ± 38.4 175.5 ± 43.8 0.002*
30 min. 129.8 ± 42.3 173.4 ± 44.2 0.003*
40 min. 129.6 ± 38.8 170.9 ± 38.4 0.002*
50 min. 128.9 ± 39.5 169.5 ± 38.1 0.002*
60 min. 125.9 ± 36.8 169.3 ± 38.3 0.001*
70 min. 123.0 ± 42.1 170.0 ± 39.9 0.013*
80 min. 133.9 ± 43.8 185.0 ± 30.4 0.006*
Group I: magnesium group, Group II: control group
Data are as mean ± SD
*Statistically significant
ml milliliter
Table 5 Respiratory rate in both groups





After induction 23.8 ± 0.6 30.2 ± 1.3 0.001*
10 min. 23.8 ± 0.6 28.3 ± 1.3 0.001*
20 min. 24.2 ± 0.7 26.3 ± 1.0 0.002*
30 min. 23.3 ± 0.7 25.4 ± 1.0 0.002*
40 min. 22.4 ± 0.5 25.2 ± 1.3 0.012*
50 min. 22.5 ± 0.8 25.1 ± 1.3 0.054*
60 min. 22.5 ± 0.8 25.2 ± 1.3 0.034*
70 min. 24.5 ± 0.9 25.1 ± 1.5 0.280
80 min. 24.7 ± 1.0 24.8 ± 1.4 0.897
Group I: magnesium group, Group II: control group
Data are as mean ± SD
*Statistically significant
Respiratory rate is measured in a breath per minute
Table 6 End tidal carbon dioxide (mmHg) in both groups





After induction 39.6 ± 13.9 37.3 ± 1.6 0.466
10 min. 39.7 ± 15.5 37.3 ± 1.5 0.486
20 min. 40.2 ± 17.7 36.8 ± 1.4 0.397
30 min. 39.7 ± 16.6 36.4 ± 1.4 0.375
40 min. 39.1 ± 14.2 36.0 ± 1.4 0.330
50 min. 38.9 ± 13.3 35.8 ± 1.4 0.299
60 min. 38.9 ± 14.3 35.5 ± 1.6 0.303
70 min. 36.6 ± 1.7 35.3 ± 1.6 0.650
80 min. 37.1 ± 1.3 34.5 ± 1.6 0.522
Group I: magnesium group, Group II: control group
Data are as mean ± SD
mmHg millimeter mercury








After induction 66.8 ± 6.5 67.1 ± 5.2 0.894
10 min. 61.7 ± 5.4 65.6 ± 4.8 0.055
20 min. 56.1 ± 3.2 63.7 ± 2.3 0.041*
30 min. 52.6 ± 5.4 56.2 ± 3.6 0.036*
40 min. 52.3 ± 4.5 55.3 ± 2.4 0.045*
50 min. 48.1 ± 4.7 55.2 ± 4.6 0.040*
60 min. 45.9 ± 3.4 53.2 ± 4.9 0.047*
70 min. 45.2 ± 1.3 52.6 ± 6.1 0.043*
80 min. 46.3 ± 1.5 51.1 ± 5.6 0.041*
Group I: magnesium group, Group II: control group
Data are as mean ± SD
*Statistically significant difference
BIS Bispectral Index Scale
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examined the effect of magnesium on intraoperative
muscle relaxants requirement [21] or post-operative emer-
gence agitation [10, 19, 20]. But they did not examine the
effect of magnesium on bi-spectral index.
Magnesium sulphate has been used intravenously at
dose of 25–75 mg/kg [22] for treatment of asthma in
children in five randomized trials [23–27]. For magne-
sium dosing, we followed H.S. Na et al. [21] who used
magnesium at dose of 50 mg/kg bolus followed by
15 mg/kg without reporting any side effects.
Lim B. et al. [28] concluded that pressure support
ventilation did not produce significant clinical outcome
when compared with spontaneous ventilation during
pediatric anesthesia increased tidal volume and decreased
end-tidal carbon dioxide. We used spontaneous ventila-
tion in our study to examine the effect of magnesium
sulphate on respiratory parameters.
Our study revealed that the magnesium produced a
significant decrease in respiratory rate and tidal volume
without affecting end-tidal CO2 concentration or oxygen
saturation that can be explained by anesthetic and
analgesic properties of magnesium. No hemodynamic
instability or adverse events were reported.
Although no hemodynamic side effects were reported in
our study, it is important to note that we used atropine as
a premedication in all recruited patients according to the
local protocol in our hospital. This may alter the accuracy
of estimating possible hemodynamic effects of magnesium
in an age group characterized by heart rate dependent car-
diac output.
In conclusion, our study represents another evidence
for the effect of magnesium sulphate as an adjunct to
general anesthesia, but this time in the pediatric age
group that has received a limited number of studies. We
also used the bi-spectral index scale as a monitor to as-
sess the direct central effect of magnesium sulphate.
Limitations and future plan
One of the limitations in our study is that we did not
measure perioperative plasma concentration of mag-
nesium. Correlation between magnesium plasma level
and BIS values can be useful in a future study for
more accurate assessment of the direct central effect
of magnesium sulphate guided by the BIS.
Conclusion
Magnesium sulphate as an adjuvant to general anesthesia
in pediatric patients remarkably reduced time to reach BIS
values of 60 by about 10 min and produced significantly
less BIS values. Magnesium resulted in significantly lower
tidal volume, lower respiratory rate but without a statisti-
cally significant hypercapnia. We did not report any
hemodynamic instability or complications.
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